Company: HQL
Filing Date: 2025-06-09
Form Type: N-CSRS
Source: 0001104659-25-057746
Chunk: 36

Company: abrdn Life Sciences Investors
Filing Date: 2025-06-09
Form: N-CSRS
Chunk 36
---
     |                 | — |     |       3,326,419 |
| Month #3 (Dec. 1, 2024 — Dec. 31, 2024) |     |               | — |     |                | — |     |                 | — |     |       3,326,419 |
| Month #4 (Jan. 1, 2025 — Jan. 31, 2025) |     |               | — |     |                | — |     |                 | — |     |       3,326,419 |
| Month #5 (Feb. 1, 2025 — Feb. 28, 2025) |     |               | — |     |                | — |     |                 | — |     |       3,326,419 |
| Month #6 (Mar. 1, 2025 — Mar. 31, 2025) |     |               | — |     |                | — |     |                 | — |     |       3,326,419 |
| Total                                   |     |               | — |     | $              | — |     |                 | — |     |                 |

| (1) | On June 30, 2011, the share repurchase program was announced, which has been subsequently reviewed and approved by the Board of Trustees. In March 2024, the Board approved the renewal of the repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares in the open market for a one-year period ending July 14, 2025. |

Item 15. Submission of Matters to a Vote of Security Holders. During the period ended March 31, 2025, there were no material changes to the procedures by which shareholders may recommend nominees to the Registrant’s Board of Trustees. Item 16. Controls and Procedures.

| (a) | The Registrant’s principal executive and principal financial officers, or persons performing similar                                          
 functions, have concluded that the Registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under                         
 the Investment Company Act of 1940 (the “Act”) (17 CFR 270.30a-3(c))) are effective, as of a date within 90 days of the filing                
 date of the report that includes the disclosure required by this paragraph, based on the evaluation of these controls and procedures required 
 by Rule 30